GlobeNewswire Inc.··Seres Therapeutics, Inc.Seres Therapeutics Swings to $5.7M Profit on Nestlé VOWST Sale, Eyes 2026 Clinical Data
Seres Therapeutics swung to $5.7M 2025 profit from $125.8M loss, boosted by Nestlé VOWST sale, with $45.8M cash funding ops through Q3 2026.
MCRBclinical trialinflammatory bowel disease